Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Lipid Regulating Agents

Antihypertensive Agents

Bone Density Conservation Agents

Anti-Infective Agents

Androgens

Simvastatin

Rosuvastatin Calcium

Atorvastatin

Angiotensin Receptor Antagonists

Pravastatin

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Angiotensin-Converting Enzyme Inhibitors

Calcium

Calcium, Dietary

Enzyme Inhibitors

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

HIV Protease Inhibitors

Protease Inhibitors

The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate.

The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.

Standardized advice on healthy diet practices.

Nutrition

Standardized advice on exercise including strength training and resistance training exercises.

Exercise

Advice to quit smoking, if applicable, and on available aids to quit smoking,

Smoking cessation

Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.

Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)

Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.

ACE inhibitor

Sarah Karampatos, BASc, MSc

Steven Agapay, BSc

Priyanshu Nain

Avirup Guha

Terry Christenson

Charles Porter

Aaron Sverdlov

Sindhu Mohanty

Tania Moujaber

Ryan Appleton

Agnes Lagula

Braden Higgs

Tonia Bromley

Joseph Selvanayagam

Ana Araujo

joao Borges

Thais Ribeiro

Livia Pereira

Aline Carlos

Livia Oliveira

Maynara Martins

Carlos Nakashima

Gabrielly Lech

Cesar Dusilek

Carlos Rochitti

Gustavo Marques

Nathalia da Silva

Jurema Lima

Fernanda Uggeri

Rafaela Piccoli

Ana Silveira

Felipe Valle

Indianara Porgere

Katsuki Tiscoski

Gabriela Crestani

Eduardo Schlabendorff

Nelmara Camargo

Aline Fantinati

Mayra Frankenfeld

Gabriela de Queiroz

Murillo Antunes

Adriana Coutinho

Debora Campos

Patricia Beato

Barbara Lacava De Aquino

Daniel Araujo

Hugo Morelli

Mauro Hernandes

Daniela de Santana

Luis Eduardo Silva Moz

Antonia Rodrigues

Ariel Kann

Valquiria Ritter

Maristela Miranda

Marina Leonardo

Ivanize Alves

Cristiano Freitas Souza

Beatriz Nascimento

Ludhmila Hajjar

Camila Caroline

Denise Da Silva

Roberto Odebrecht Rocha

Marcio Ferraz

Jose Mauricio Mota

Mona Mirshahi

Dr. Bobby Shayegan, MD,FRCSC

Shauna Szendrey

Dr. Jehonathan Pinthus, MD,FRCS(C),PhD

Affaan Mahmud

Dr. Robert Siemens, MD,FRCSC

Stephanie O'Brien

Darin Gopaul, MD

Cadence Baker

Dr. Patrick Luke, MD,FRCSC

Nidhi Shah

Joseph Chin, MD, FRCSC

Vaibhav Chudasama

Ian Brown, BSc, MD, FRCPC

David Yachnin, ND, MSc

Dr. Luke Lavallee, MDCM,MSc,FRCSC

Marlene Kebabdjian

Dr. Laurence Klotz, MD,FRCS(C)

Imene Chergui

Dr. Emmanuelle Duceppe, MD,FRCPC

Kelli Dimayuga

Dr. Tamim Niazi, MDCM

Anabel Grullon

Nawar Hanna, MD, MSc

Bersabeh Hailemariam

Negareh Mousavi, MD

Audrey Larouche

Dr. Vincent Fradet, MD,PhD,FRCSC

Elsie Morneau

Robert Sabbagh, MSc, MD, FRCSC

Jose Enrique Cita

Anna Maria Ramos Franco

Nicolas Villareal

Brayan Daniel Cordoba Melo

Juan Esteban Gomez Mesa

Anna Michael

Elena Agronov Kaif

Zaza Iakobishvili

Natali Oginets

Alon Eisen

Marina Liberzon

Limor Ben Zvi

David Sarid

Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

RADICAL PC describes two prospective studies, one of which is embedded in the other. RADICAL PC1 is a prospective cohort study of men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit. Its goal will be to identify factors associated with the development of cardiovascular disease among men with prostate cancer, with a particular focus on Androgen Deprivation Therapy. RADICAL PC2 is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2 will test a systematic approach to modifying cardiovascular and lifestyle risk factors in men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit.

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)

Cognitive function, as measured by the DSS test.

Handgrip strength, as measured using the JAMAR Dynamometer.

Development of castrate-resistant prostate cancer

The primary efficacy outcome is the occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure, or arterial revascularization.

The occurrence of the composite of all-cause mortality, myocardial infarction, stroke, or heart failure.

The composite of cardiovascular death, myocardial infarction, or stroke.

The composite of cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, or unstable, new or worsening angina.

Prostate Cancer Canada

Canadian Cancer Society (CCS)

McMaster University

Spots Global Cancer Trial Database for statin (such as simvastatin, atorvastatin, rosuvastatin, pravastatin)